SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma
Clinical trial NCT07749859 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07749859
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-01
- Primary completion
- 2028-07-01
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.